1. Introduction {#sec1}
===============

Creatine kinase (CK) (ATP: creatine kinase N-phosphotransferase, EC 2.7.3.2) is thought to be crucial for intracellular transport and the storage of high energy phosphate because it catalyzes the reversible transfer of a phosphoryl group from MgATP to creatine, which leads to the creation of phosphocreatine and MgADP \[[@B1]\]. CK plays an important role in the cellular energy metabolism of vertebrates, and it is widely distributed in tissues that require a lot of energy \[[@B2]\]. Several types of CK are expressed in various tissues: the muscle and brain types of CK are the most common, and three different isoenzymes that include CK-MM (the muscle type homodimer), CK-BB (the brain type homodimer), and CK-MB (the muscle plus brain type heterodimer) originate from these two common types. CK is an important serum marker for myocardial infarction. Various types of CKs (the muscle, brain, and mitochondrial types) are thought to be important not only in the diagnosis of myocardial infarction, cardiac hypertrophy, and muscular dystrophy but also for studies of some other serious diseases, including Alzheimer\'s disease, Parkinson\'s disease, and psoriasis \[[@B3]--[@B8]\].

CK-BB is associated with several pathologies, including neurodegenerative and age-related diseases. Recently, Chang et al. \[[@B9]\] reported an important role for CK-BB in osteoclast-mediated bone resorption, which was found using a proteomics approach. They found that CK-BB is greatly increased during osteoclastogenesis and suggested that it represents a potential target for antiresorptive drug development. CK-BB interacts with the potassium-chloride cotransporter 3, which is involved in the pathophysiology of hereditary motor and sensory neuropathy with agenesis of the corpus callosum \[[@B10]\]. Previous studies \[[@B11], [@B12]\] have reported that CK-BB is involved in Alzheimer\'s disease (AD) as an oxidatively modified protein. This suggests that oxidatively damaged CK-BB may be associated with aging and age-related neurodegenerative disorders such as AD.

CK-MM is a good model to use for studying folding pathways because of several characteristics: (i) it is a dimer that consists of two identical subunits, each with an N-terminal domain with about 100 residues and a C-terminal domain with about 250 residues connected by a long linker \[[@B13]\]; (ii) extensively denatured CK can be renatured spontaneously with restoration of its enzymatic activity in the absence of any external assistance \[[@B14]\]; (iii) its folding pathway is complicated and involves several intermediates \[[@B15], [@B16]\]; (iv) conformational changes of the secondary and tertiary structures can be easily measured by monitoring activity changes \[[@B14], [@B15]\]; (v) protein-protein interactions, including molecular chaperones, are observed during refolding \[[@B17], [@B18]\].

In this study, we obtained computational predictions of the binding proteins by using two types of CK (CK-BB and CK-MM) as hub proteins in bioinformatic algorithms. As a result, we obtained 208 protein lists in the interaction networks via application of both muscle and brain types of CK. Determination of the binding factors and functions of CK can further promote our understanding of the physiological roles of CK.

2. Materials and Methods {#sec2}
========================

2.1. PPI Mappings: PEIMAP and PSIMAP Algorithms {#sec2.1}
-----------------------------------------------

We present the functionally classified protein-protein interactions on the basis of the cell cycle, cell transport, oxidoreductase, and apoptosis. PPI resources were assembled from a combination of several experimental protein interaction databases. The protein interaction resources included six databases: DIP \[[@B19]\], BIND \[[@B20]\], IntAct \[[@B21]\], MINT \[[@B22]\], HPRD \[[@B23]\], and BioGrid \[[@B24]\]. We performed a redundancy test to remove identical protein sequences from the interaction databases. The databases contain 116,773 proteins and 229,799 interactions.

PPI prediction uses most of the major types of PPI algorithms. They are (1) Protein Structural Interactome MAP (PSIMAP), a method that uses the structural domain of the SCOP (Structural Classification of Proteins) database \[[@B25]\] and (2) Protein Experimental Interactome MAP (PEIMAP), a common method that uses public resources of experimental protein interaction information such as HPRD, BIND, DIP, MINT, IntAct; and BioGrid. The basic procedure of PSIMAP is to infer interactions between proteins by using their homologs. Interactions among domains or proteins for known PDB (Protein Data Bank) structures are the basis for the prediction. If an unknown protein has a homolog to a domain, then PSIMAP assumes that the query has the probability to interact with its homolog\'s partners. This concept is called "homologous interaction." The original interaction between two proteins or domains is based on the Euclidean distance. Therefore, PSIMAP gives a structure-based interaction prediction \[[@B26]\]. PEIMAP was constructed by combining several experimental protein-protein interaction databases. We carried out a redundancy check to remove identical protein sequences from the source interaction databases. The image was made by the Pajak2.00 program (<http://vlado.fmf.uni-lj.si/pub/networks/pajek/>).

3. Results and Discussion {#sec3}
=========================

We identified potential candidates through protein-protein interaction predictions made using various protein interaction resources. By analyzing the hub protein of the networks with metrics such as degree and centrality, we detected 123 potential candidates for CKB interacting (direct or indirect) factors and 85 candidates for CKM.

In [Figure 1](#fig1){ref-type="fig"}, interacting factors such as NFKB1 (NP_003989, nuclear factor of kappa light polypeptide gene enhancer in B-cells 1), MYOC (NP_000252; myocilin, trabecular meshwork inducible glucocorticoid response), MYOM2 (NP_003961; myomesin (M-protein) 2, 165 kDa), FHL2 (NP_001034581, four-and-a-half LIM domains 2), HIF1AN (NP_060372, hypoxia-inducible factor 1, alpha subunit inhibitor), ASB9 (NP_076992, ankyrin repeat and SOCS box-containing 9), and CKM (NP_001815, creatine kinase, muscle) were elucidated. Interestingly, NFKB1 was detected as a hub protein interacting with CK-BB in our results. In [Figure 2](#fig2){ref-type="fig"}, we obtained results similar to those from [Figure 1](#fig1){ref-type="fig"}, where NFKB1, MYOC, MYOM2, FHL2, HIF1AN, ASB9, and CKM were detected as interacting factors that were directly or indirectly associated with CKB. NFKB1, CKM, and ASB9 interacted with CKB directly.

In the same way, we detected the CKM-associated proteins as shown in [Figure 3](#fig3){ref-type="fig"} with 80% sequence identity. As a result, we found that CKB, FHL2, MYOC, ASB9, HIF1AN, NFKB1, TTN (NP_596870, titin), MYH9 (NP_002464, myosin, heavy chain 9, non-muscle), and ITGA7 (NP_002197, integrin, alpha 7) mainly interacted with CKM at 80% sequence identity. At the level of 100% identity, we found that MYOM2, CKB, FHL2, and MYOC directly interacted with CKM as shown in [Figure 4](#fig4){ref-type="fig"}. In addition to these factors, complete lists of factors that interacted with CKB and CKM in a direct or indirect manner are shown in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}. After overlapping the results from Figures [1](#fig1){ref-type="fig"}[to 4](#fig4){ref-type="fig"}, we found that NFKB1, FHL2, and MYOC were still detected as hub proteins in [Figure 5](#fig5){ref-type="fig"}.

NFKB1 (also known as p50 or NF-kappaB) is a well-known transcription regulator that is responsible for the expression and regulation of many genes for immune response, cell adhesion, differentiation, proliferation, angiogenesis, and apoptosis \[[@B27]--[@B31]\]. It translocates into the nucleus and stimulates the expression of many genes involved in various biological functions. NFKB1 is also associated with a number of inflammatory diseases such as lymphoma \[[@B32]\], Alzheimer disease \[[@B33]\], psoriatic arthritis \[[@B34]\], breast cancer \[[@B35], [@B36]\], and rheumatoid arthritis \[[@B37]\]. Activation of NFKB1 requires binding of NF-kappaB essential modulator (NEMO) to ubiquitinated substrates \[[@B38]\]. With respect to an association with CK, it has been reported that NFKB1 is mostly associated with myocardial ischemia/reperfusion. During reperfusion, the absence of poly(ADP-ribose) polymerase-1 (PARP-1) leads to a reduction of myocardial apoptosis, which is associated with reduced NFKB1 activation \[[@B39], [@B40]\], and proteasome inhibition ablates activation of NFKB1 in myocardial reperfusion and reduces reperfusion injury \[[@B41]\]. Myocardial injury was assessed by measuring the serum levels of CK, and CK was reduced in serum along with reduction of NFKB1 activation.

FHL2 is a member of the human four-and-a-half-LIM-only protein family, which consists of the members FHL1, FHL2, FHL3, FHL4, and ACT. These proteins function in various cellular processes, including regulation of cell survival, transcription, and signal transduction \[[@B42]\]. FHL2 contains an LIM domain, one of the protein-protein interaction motifs, which allows specific proteins to combine with certain partners. The specificity of a protein-protein interaction can be obtained by an interaction code predicted by conserved amino acid sequences. The interaction of FHL2 with transcription factors and other proteins involved in cancer development was examined. Since transcription factors control all fundamental developmental and homeostatic processes, transcriptional cofactors such as FHL2 are likely to contribute to human carcinogenesis and are of clinical importance in various forms of cancer \[[@B43]\], including leukemia \[[@B44]\]. With respect to an association with CK, Chung et al. \[[@B45]\] reported that FHL2 (developmentally enhanced phosphotransfer enzyme-anchoring protein) amalgamated the myofibrillar CK metabolic signaling circuit, providing an energetic continuum between mitochondria and the nascent contractile machinery in a murine embryonic stem cell cardiac differentiation model. They reported that CK-M clustered around developing myofibrils, sarcolemma, and the perinuclear compartment, whereas CK-B was tightly associated with myofibrillar alpha-actinin, forming wire-like structures extending from the nuclear compartment to the sarcolemma. FHL2 was also increased in myocardial ischemia-reperfusion injury, where IL-6 and IL-8 mRNA are upregulated in human cardiac myocytes \[[@B46]\].

Recently, ASB9 was found to interact with ubiquitous mitochondrial CK \[[@B47]\]. The ankyrin repeat domains of ASB9 can associate with the substrate binding site of CK in a SOCS box-independent manner. The overexpression of ASB9 induces ubiquitination of CK. ASB9 reduces CK activities and cell growth and negatively regulates cell growth. ASB9 is a member of the ankyrin repeat and is a suppressor of the cytokine signaling (SOCS) box protein family. It can interact with the SOCS box domain of the elongin B-C adapter complex and can further complex with the cullin and ring box proteins to form E3 ubiquitin ligase complexes \[[@B48]\]. These complexes may be involved in specific substrate-recognition for ubiquitination and degradation and mediate the substrate-recognition of the E3 ubiquitin ligases.

The interaction between CK and MYOC has not been elucidated. However, MYOC has a cytoskeletal function, and this implies that it may interact with CK somehow. MYOC is expressed in many ocular tissues including the trabecular meshwork \[[@B49]\], which is a specialized eye tissue that is essential in regulating intraocular pressure. MYOC mutations have been identified as the cause of hereditary juvenile-onset open-angle glaucoma \[[@B50]\].

Researchers could apply computational prediction by PPI mapping to help determine target proteins. Since the next step in the functional study of interesting proteins/genes is a time- and cost-consuming process, the number of target proteins is limited; hence, for the right choice, computational prediction on the basis of database information could be critical at this step. Functional studies can be further conducted using a mouse model and a large number of clinical samples. Final confirmation and CK mechanisms could then be more clearly evaluated for developing drugs to effectively treat CK-related diseases.

The functions of most of the candidate proteins predicted in this study have not been well reported in skin diseases or in the pathogenesis of other diseases. We provide new information regarding these candidate proteins\' interaction with CK, as well as the involvement of several hub proteins such as NFKB1, FHL2, ASB9, and MYOC. Although we do not suggest a direct role of any candidate protein in skin diseases, we provide candidate proteins to be targeted in further studies of CK-associated diagnostic markers and/or treatment of corresponding skin conditions. Furthermore, we also provide some insights into understanding the responses of CK in skin.
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![PPI map for CKB as a target hub protein with the 80% identity. Labels with red color indicate the hub protein of targeting. The image was made by the aiSee program (<http://www.aisee.com/>).](ER2011-328249.001){#fig1}

![PPI map for CKB as a target hub protein with the 100% identity. The methodological conditions were the same as for [Figure 1](#fig1){ref-type="fig"} except the identity.](ER2011-328249.002){#fig2}

![PPI map for CKM as a target hub protein with the 80% identity. Labels with red color indicate the hub protein of targeting. The image was made by the aiSee program (<http://www.aisee.com/>).](ER2011-328249.003){#fig3}

![PPI map for CKM as a target hub protein with the 100% identity. The methodological conditions were the same as for [Figure 3](#fig3){ref-type="fig"} except the identity.](ER2011-328249.004){#fig4}

![Overlapping map between CKB and CKM PPI maps. Data were input by using the results from Figures [1](#fig1){ref-type="fig"}[to 4](#fig4){ref-type="fig"}.](ER2011-328249.005){#fig5}

###### 

Gene lists for the analyses of the PEIMAP and PSIMAP using CK-BB as a hub protein with 100% identity.

  Gene ID   Gene symbol   Full name
  --------- ------------- ---------------------------------------------------------------------------------------------
  6256      RXRA          Retinoid X receptor, alpha
  3309      HSPA5         Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa)
  3320      HSP90AA1      Heat shock protein 90 kDa alpha (cytosolic), class A member 1
  2908      NR3C1         Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
  6778      STAT6         Signal transducer and activator of transcription 6, interleukin-4 induced
  3146      HMGB1         High-mobility group box 1
  3301      DNAJA1        DnaJ (Hsp40) homolog, subfamily A, member 1
  4221      MEN1          Multiple endocrine neoplasia I
  3312      HSPA8         Heat shock 70 kDa protein 8
  3840      KPNA4         Karyopherin alpha 4 (importin alpha 3)
  2274      FHL2          Four-and-a-half LIM domains 2
  4792      NFKBIA        Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
  57805     KIAA1967      KIAA1967
  3185      HNRNPF        Heterogeneous nuclear ribonucleoprotein F
  203068    TUBB          Tubulin, beta
  6774      STAT3         Signal transducer and activator of transcription 3 (acute-phase response factor)
  4670      HNRNPM        Heterogeneous nuclear ribonucleoprotein M
  1997      ELF1          E74-like factor 1 (ets domain transcription factor)
  113457    TUBA3D        Tubulin, alpha 3D
  1999      ELF3          E74-like factor 3 (ets domain transcription factor, epithelial-specific)
  5591      PRKDC         Protein kinase, DNA-activated, catalytic polypeptide
  708       C1QBP         Complement component 1, q subcomponent binding protein
  2274      FHL2          Four-and-a-half LIM domains 2
  3313      HSPA9         Heat shock 70 kDa protein 9 (mortalin)
  8600      TNFSF11       Tumor necrosis factor (ligand) superfamily, member 11
  3659      IRF1          Interferon regulatory factor 1
  84617     TUBB6         Tubulin, beta 6
  7280      TUBB2A        Tubulin, beta 2A
  2908      NR3C1         Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
  2908      NR3C1         Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
  8517      IKBKG         Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma
  7295      TXN           Thioredoxin
  10318     TNIP1         TNFAIP3 interacting protein 1
  4793      NFKBIB        Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta
  3065      HDAC1         Histone deacetylase 1
  3551      IKBKB         inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
  1152      CKB           Creatine kinase, brain
  4069      LYZ           Lysozyme (renal amyloidosis)
  140462    ASB9          Ankyrin repeat and SOCS box-containing 9
  4653      MYOC          Myocilin, trabecular meshwork inducible glucocorticoid response
  6774      STAT3         Signal transducer and activator of transcription 3 (acute-phase response factor)
  3660      IRF2          Interferon regulatory factor 2
  7278      TUBA3C        Tubulin, alpha 3c
  4221      MEN1          Multiple endocrine neoplasia I
  5966      REL           v-rel reticuloendotheliosis viral oncogene homolog (avian)
  1147      CHUK          Conserved helix-loop-helix ubiquitous kinase
  55922     NKRF          NFKB repressing factor
  2113      ETS1          v-ets erythroblastosis virus E26 oncogene homolog 1 (avian)
  64332     NFKBIZ        Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta
  51773     RSF1          Remodeling and spacing factor 1
  5971      RELB          v-rel reticuloendotheliosis viral oncogene homolog B
  1832      DSP           Desmoplakin
  347733    TUBB2B        Tubulin, beta 2B
  2353      FOS           v-fos FBJ murine osteosarcoma viral oncogene homolog
  9325      TRIP4         Thyroid hormone receptor interactor 4
  4435      CITED1        Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1
  22984     PDCD11        Programmed cell death 11
  790       CAD           Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase
  1326      MAP3K8        Mitogen-activated protein kinase kinase kinase 8
  1917      EEF1A2        Eukaryotic translation elongation factor 1 alpha 2
  9172      MYOM2         Myomesin (M-protein) 2, 165 kDa
  10856     RUVBL2        RuvB-like 2 (E. coli)
  1158      CKM           Creatine kinase, muscle
  808       CALM3         Calmodulin 3 (phosphorylase kinase, delta)
  672       BRCA1         Breast cancer 1, early onset
  801       CALM1         Calmodulin 1 (phosphorylase kinase, delta)
  293       SLC25A6       Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6
  3310      HSPA6         Heat shock 70 kDa protein 6 (HSP70B′)
  2908      NR3C1         Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
  136319    MTPN          Myotrophin
  2274      FHL2          Four-and-a-half LIM domains 2
  9093      DNAJA3        DnaJ (Hsp40) homolog, subfamily A, member 3
  4628      MYH10         Myosin, heavy chain 10, non-muscle
  4221      MEN1          Multiple endocrine neoplasia I
  6774      STAT3         Signal transducer and activator of transcription 3 (acute-phase response factor)
  3839      KPNA3         Karyopherin alpha 3 (importin alpha 4)
  57805     KIAA1967      KIAA1967
  2908      NR3C1         Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
  1869      E2F1          E2F transcription factor 1
  55662     HIF1AN        Hypoxia-inducible factor 1, alpha subunit inhibitor
  79155     TNIP2         TNFAIP3 interacting protein 2
  9532      BAG2          BCL2-associated athanogene 2
  6421      SFPQ          Splicing factor proline/glutamine-rich (polypyrimidine tract binding protein associated)
  2908      NR3C1         Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
  10627     MRCL3         Myosin regulatory light chain MRCL3
  7431      VIM           Vimentin
  672       BRCA1         Breast cancer 1, early onset
  2274      FHL2          Four-and-a-half LIM domains 2
  4221      MEN1          Multiple endocrine neoplasia I
  672       BRCA1         Breast cancer 1, early onset
  4221      MEN1          Multiple endocrine neoplasia I
  3836      KPNA1         Karyopherin alpha 1 (importin alpha 5)
  3093      UBE2K         Ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast)
  805       CALM2         Calmodulin 2 (phosphorylase kinase, delta)
  5970      RELA          v-rel reticuloendotheliosis viral oncogene homolog A (avian)
  9782      MATR3         Matrin 3
  8600      TNFSF11       Tumor necrosis factor (ligand) superfamily, member 11
  8607      RUVBL1        RuvB-like 1 (E. coli)
  4627      MYH9          Myosin, heavy chain 9, nonmuscle
  23421     ITGB3BP       Integrin beta 3 binding protein (beta3-endonexin)
  140462    ASB9          Ankyrin repeat and SOCS box-containing 9
  4841      NONO          Non-POU domain containing, octamer-binding
  9276      COPB2         Coatomer protein complex, subunit beta 2 (beta prime)
  4221      MEN1          Multiple endocrine neoplasia I
  1213      CLTC          Clathrin, heavy chain (Hc)
  292       SLC25A5       Solute carrier family 25 (Mitochondrial carrier; adenine nucleotide translocator), member 5
  4066      LYL1          Lymphoblastic leukemia-derived sequence 1
  64332     NFKBIZ        Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta
  5531      PPP4C         Protein phosphatase 4 (formerly X), catalytic subunit
  8091      HMGA2         High-mobility group AT-hook 2
  6202      RPS8          Ribosomal protein S8
  1051      CEBPB         CCAAT/enhancer binding protein (C/EBP), beta
  222643    UNC5CL        Unc-5 homolog C (C. elegans)-like
  4790      NFKB1         Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
  71        ACTG1         Actin, gamma 1
  3312      HSPA8         Heat shock 70 kDa protein 8
  9782      MATR3         Matrin 3
  3320      HSP90AA1      Heat shock protein 90 kDa alpha (cytosolic), class A member 1
  4637      MYL6          Myosin, light chain 6, alkali, smooth muscle and nonmuscle
  2908      NR3C1         Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
  4793      NFKBIB        Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta
  688       KLF5          Kruppel-like factor 5 (intestinal)
  672       BRCA1         Breast cancer 1, early onset

###### 

Gene lists for the analyses of the PEIMAP and PSIMAP using CK-MM as a hub protein with 100% identity.

  Gene ID   Gene symbol   Full name
  --------- ------------- --------------------------------------------------------------------------------------------------------
  1889      ECE1          Endothelin-converting enzyme 1
  5981      RFC1          Replication factor C (activator 1) 1, 145 kDa
  226       ALDOA         Aldolase A, fructose-bisphosphate
  2335      FN1           Fibronectin 1
  9372      ZFYVE9        Zinc finger, FYVE domain containing 9
  60        ACTB          Actin, beta
  3688      ITGB1         Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
  7273      TTN           Titin
  2274      FHL2          Four-and-a-half LIM domains 2
  4853      NOTCH2        Notch homolog 2 (Drosophila)
  2512      FTL           Ferritin, light polypeptide
  1192      CLIC1         Chloride intracellular channel 1
  2274      FHL2          Four-and-a-half LIM domains 2
  5313      PKLR          Pyruvate kinase, liver and RBC
  302       ANXA2         Annexin A2
  7704      ZBTB16        Zinc finger and BTB domain containing 16
  2200      FBN1          Fibrillin 1
  27332     ZNF638        Zinc finger protein 638
  92086     GGTLC1        Gamma-glutamyltransferase light chain 1
  713       C1QB          Complement component 1, q subcomponent, B chain
  3029      HAGH          Hydroxyacylglutathione hydrolase
  5664      PSEN2         Presenilin 2 (Alzheimer disease 4)
  7086      TKT           Transketolase (Wernicke-Korsakoff syndrome)
  4176      MCM7          Minichromosome maintenance complex component 7
  1152      CKB           Creatine kinase, brain
  1499      CTNNB1        Catenin (cadherin-associated protein), beta 1, 88 kDa
  140462    ASB9          Ankyrin repeat and SOCS box-containing 9
  9457      FHL5          Four-and-a-half LIM domains 5
  4653      MYOC          Myocilin, trabecular meshwork inducible glucocorticoid response
  3029      HAGH          Hydroxyacylglutathione hydrolase
  7704      ZBTB16        Zinc finger and BTB domain containing 16
  3675      ITGA3         Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)
  226       ALDOA         Aldolase A, fructose-bisphosphate
  3689      ITGB2         Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
  3688      ITGB1         Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
  302       ANXA2         Annexin A2
  92086     GGTLC1        Gamma-glutamyltransferase light chain 1
  3679      ITGA7         Integrin, alpha 7
  2023      ENO1          Enolase 1, (alpha)
  9172      MYOM2         Myomesin (M-protein) 2, 165 kDa
  1158      CKM           Creatine kinase, muscle
  4790      NFKB1         Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)
  2         A2M           Alpha-2-macroglobulin
  3688      ITGB1         Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
  56944     OLFML3        Olfactomedin-like 3
  1281      COL3A1        Collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)
  2274      FHL2          Four-and-a-half LIM domains 2
  3688      ITGB1         Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
  118427    OLFM3         Olfactomedin 3
  22900     CARD8         Caspase recruitment domain family, member 8
  3488      IGFBP5        Insulin-like growth factor binding protein 5
  7132      TNFRSF1A      Tumor necrosis factor receptor superfamily, member 1A
  226       ALDOA         Aldolase A, fructose-bisphosphate
  3675      ITGA3         Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)
  51455     REV1          REV1 homolog (S. cerevisiae)
  6421      SFPQ          Splicing factor proline/glutamine-rich (polypyrimidine tract binding protein associated)
  302       ANXA2         Annexin A2
  4633      MYL2          Myosin, light chain 2, regulatory, cardiac, slow
  8880      FUBP1         Far upstream element (FUSE) binding protein 1
  2274      FHL2          Four-and-a-half LIM domains 2
  3688      ITGB1         Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
  27332     ZNF638        Zinc finger protein 638
  3673      ITGA2         Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)
  203       AK1           Adenylate kinase 1
  4627      MYH9          Myosin, heavy chain 9, non-muscle
  5213      PFKM          Phosphofructokinase, muscle
  140462    ASB9          Ankyrin repeat and SOCS box-containing 9
  7076      TIMP1         TIMP metallopeptidase inhibitor 1
  5176      SERPINF1      Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1
  3694      ITGB6         Integrin, beta 6
  59        ACTA2         Actin, alpha 2, smooth muscle, aorta
  4176      MCM7          Minichromosome maintenance complex component 7
  10487     CAP1          CAP, adenylate cyclase-associated protein 1 (yeast)
  7046      TGFBR1        Transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53 kDa)
  3543      IGLL1         Immunoglobulin lambda-like polypeptide 1
  5313      PKLR          Pyruvate kinase, liver and RBC
  51455     REV1          REV1 homolog (S. cerevisiae)
  10296     MAEA          Macrophage erythroblast attacher
  3911      LAMA5         Laminin, alpha 5
  2597      GAPDH         Glyceraldehyde-3-phosphate dehydrogenase
  975       CD81          CD81 molecule
  92086     GGTLC1        Gamma-glutamyltransferase light chain 1
  1915      EEF1A1        Eukaryotic translation elongation factor 1 alpha 1
  5664      PSEN2         Presenilin 2 (Alzheimer disease 4)
  1278      COL1A2        Collagen, type I, alpha 2
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